Shop by goal
Popular compounds
Research resources
Recently viewed
Retatrutide vs Semaglutide: Triple Agonist vs GLP-1, Compared
Retatrutide is an investigational triple agonist (GIP + GLP-1 + glucagon); semaglutide is an FDA-approved GLP-1 single agonist. In their own trials, retatrutide reached ~24.2% mean weight reduction at 48 weeks (Phase 2) versus semaglutide’s ~14.9% at 68 weeks (STEP-1). They have never been tested head-to-head , and only semaglutide is approved.
No head-to-head trial exists. The figures below come from separate studies with different populations, durations, doses and endpoints. Cross-trial percentages are indicative only — they are not evidence that one compound outperforms another. All data is presented for research context; nothing here is medical or dosing guidance.
On this page
At a glance
One receptor vs three
Semaglutide is the reference GLP-1 mono-agonist — it acts on a single incretin receptor and set the modern benchmark for the class. Retatrutide layers GIP and glucagon agonism on top of GLP-1.
Semaglutide — single
GLP-1 receptor only. The most studied, most prescribed molecule in the class, with the deepest long-term dataset.
Retatrutide — triple
GIP + GLP-1 + glucagon. Broader receptor engagement, larger early weight numbers, but far less long-term evidence.
What the trials showed
The cross-trial gap looks large, but semaglutide’s numbers come from a completed, approved programme, while retatrutide’s come from earlier-phase research still being confirmed. Depth of evidence and regulatory status weigh against a raw percentage.
Regulatory status
Semaglutide is FDA-approved (Ozempic for type 2 diabetes, Wegovy for weight management, plus an oral form). Retatrutide is investigational with no approval and is a research compound only.
Side-effect profiles
Both are dominated by dose-dependent gastrointestinal effects that ease with gradual titration in trials. Semaglutide’s safety profile is the most mature in the class thanks to years of post-approval use. Retatrutide trials additionally flagged heart-rate increases and glucagon-arm metabolic parameters that Phase 3 is designed to characterise.
Research takeaway
Retatrutide & semaglutide, lab-direct
New-U supplies both as >99% HPLC-verified research compounds with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Related reading
Frequently asked questions
In their separate trials retatrutide reached ~24.2% mean weight reduction at 48 weeks versus semaglutide’s ~14.9% at 68 weeks, but no head-to-head trial exists, so this is a cross-trial comparison only. Semaglutide is approved with mature data; retatrutide is investigational. Research context only.
Semaglutide is a single GLP-1 receptor agonist; retatrutide is a triple agonist adding GIP and glucagon receptors. Semaglutide is FDA-approved; retatrutide is still in Phase 3 trials.
No. Semaglutide (Ozempic, Wegovy) is FDA-approved. Retatrutide has no approval and is an investigational research compound.
Both are dominated by dose-dependent gastrointestinal effects. Semaglutide has the more mature safety record; retatrutide trials additionally noted heart-rate increases and glucagon-arm parameters being characterised in Phase 3.
All figures are laboratory-preparation reference points, not dosing guidance. New-U Research Compounds supplies bacteriostatic water and research compounds strictly for laboratory research use only — not for human consumption .
Research-grade · >99% HPLC purity · COA per lot
Buy Retatrutide from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io